荷兰与土耳其2型糖尿病患者对药物效果重要性差异的偏好研究表1
通过离散选择实验比较荷兰和土耳其2型糖尿病患者对口服降糖药不同效果偏好的表格数据。

基本信息
资源简介
荷兰与土耳其2型糖尿病患者对药物效果重要性差异的偏好研究表1
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集,收录 1 个文件、合计 87.62 KB,主题涵盖 type 2 diabetes mellitus、patient preferences、discrete-choice experiment、The Netherlands、Turkey,可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf》。配套论文《Achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis》发表于 Cardiovascular Diabetology(2016),DOI:10.1186/s12933-016-0391-8。源站首次发布:2021-02-25。
【数据内容】
源站原始描述:Objective: The aim of this study was to compare the importance that patients with type 2 diabetes mellitus from the Netherlands and Turkey attach to certain drug effects of oral anti-diabetic drugs. Methods: Data were collected through a cross-sectional survey containing demographic questions and a discrete choice experiment assessing preferences for oral anti-diabetic drugs. Adults from the Netherlands and Turkey were included if they had type 2 diabetes mellitus and had received a prescription…
【数据结构与技术规格】
文件数 1 个,合计 87.62 KB。table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf:application/pdf,87.62 KB。数据集 DOI:10.3389/fphar.2020.617409.s001。
【主题与分类】
源站学科分类:Toxicology (incl. Clinical Toxicology)、Basic Pharmacology、Clinical Pharmacology and Therapeutics、Clinical Pharmacy and Pharmacy Practice、Pharmaceutical Sciences、Pharmacogenomics。主题标签:type 2 diabetes mellitus、patient preferences、discrete-choice experiment、The Netherlands、Turkey。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面:https://frontiersin.figshare.com/articles/dataset/table1_Differences_in_Importance_Attached_to_Drug_Effects_Between_Patients_With_Type_2_Diabetes_From_the_Netherlands_and_Turkey_A_Preference_Study_pdf/14113538
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Munoz, Sonia Roldan; Postmus, Douwe; de Vries, Sieta T.; Arnardottir, Arna H.; Dolu, İlknur; Hillege, Hans; et al. (2021). table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf. Frontiers. Dataset
【使用注意】
· 源站最后修改于 2023-05-31,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf
- DOI:10.3389/fphar.2020.617409.s001
- 发布日期:2021-02-25
- 文件数:1 个
- 文件总体积:87.62 KB
- 源站页面:https://frontiersin.figshare.com/articles/dataset/table1_Differences_in_Importance_Attached_to_Drug_Effects_Between_Patients_With_Type_2_Diabetes_From_the_Netherlands_and_Turkey_A_Preference_Study_pdf/14113538
命令行下载
curl -L -o "table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf" "https://ndownloader.figshare.com/files/26617505"
文件清单
table1_Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study.pdf(87.62 KB)
文件总体积 87.62 KB(源站 API 实测)。
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
Objective: The aim of this study was to compare the importance that patients with type 2 diabetes mellitus from the Netherlands and Turkey attach to certain drug effects of oral anti-diabetic drugs.
Methods: Data were collected through a cross-sectional survey containing demographic questions and a discrete choice experiment assessing preferences for oral anti-diabetic drugs. Adults from the Netherlands and Turkey were included if they had type 2 diabetes mellitus and had received a prescription of an oral anti-diabetic drug in the last 4 months. The oral anti-diabetic drugs in the discrete choice experiment were described in terms of six attributes: effects on HbA1c, cardiovascular diseases, weight change, gastrointestinal adverse drug events hypoglycemic events, and bladder cancer. Multinomial logit models with country as an interaction factor were fitted.
Results: In total, 381 patients were included, 199 from the Netherlands and 182 from Turkey. Patients’ preferences toward drug effects varied between the countries. Turkish patients attached the highest importance to reducing the risk of cardiovascular diseases (relative weight: 0.51, 95% CI 0.45–0.55), followed by reducing hypoglycemic events (relative weight: 0.16, 95% CI 0.11–0.22), and reducing gastrointestinal adverse drug events (relative weight: 0.11, 95% CI 0.07–0.18). Patients from the Netherlands attached the highest importance to gastrointestinal ADEs (relative weight: 0.22, 95% CI 0.14–0.39), followed by reducing hypoglycemic events (relative weight: 0.22, 95% CI 0.16–0.25), and reducing the risk of cardiovascular diseases (relative weight: 0.20, 95% CI 0.13–0.23).
Conclusion: Patient preferences may differ across countries. Such differences should be acknowledged in regulatory decisions and clinical practice.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.3389/fphar.2020.617409.s001(source: https://frontiersin.figshare.com/articles/dataset/table1_Differences_in_Importance_Attached_to_Drug_Effects_Between_Patients_With_Type_2_Diabetes_From_the_Netherlands_and_Turkey_A_Preference_Study_pdf/14113538)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




